Market Overview:
The global bronchiectasis drugs market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of bronchiectasis, increasing awareness about the disease, and technological advancements in the field of bronchiectasis drugs. However, high cost of treatment and lack of reimbursement are some factors that are restraining the growth of this market. The global bronchiectasis drugs market is segmented on the basis of type, application, and region. On the basis of type, it is divided into antibiotics, expectorants, and other drugs. Antibiotics accounted for a major share in 2017 owing to their wide usage for treating various respiratory infections caused by bacteria or viruses. On the basis on application, it is segmented into hospital pharmacies & clinics research institutes among others).
Product Definition:
Bronchiectasis is a lung disease that causes airways, or bronchi, to become widened and damaged. This makes it difficult for the lungs to clear mucus and dirt from the airways. Bronchiectasis drugs are used to help clear mucus from the airways and keep them open.
Antibiotics:
Antibiotics are drugs that kill or inhibit the growth of bacteria. Some types of antibiotics, for example, penicillin and cephalosporin are used to treat infections caused by bacteria. The majority of antibiotics available today are synthetic; however, some natural products such as neomycin and erythromycin remain in use. Antibiotics can be administered in two ways: as a prescription drug or as an over-the-counter (OTC) product.
Expectorants:
Expectorants are drugs that help the lungs to cough up mucus. Coughing helps clear the airways of mucus, which is a common sign of respiratory infection. The expectorant drug works by relaxing the smooth muscles in the bronchi and lung, which allows more air to pass through and reach the alveolar region for exhalation.
Application Insights:
Based on application, the market is segmented into hospital bronchiectasis, clinic Bronchiectasis, other Bronchiectasis and research institutes Bronchiectasis. The other bronchitis drugs segment dominated the overall market in terms of revenue in 2017. This can be attributed to increasing prevalence of chronic respiratory diseases such as asthma and COPD which are associated with increased risk of developing lung infections. As a result,Bronchoalveolar lavage is used for the treatment of patients with these conditions to remove any potential pathogens from the airways that may cause complications during therapy or after completion of antibiotic course. Such factors are expected to drive demand for bronchitis drugs over the forecast period thereby supporting growth.
The hospital application segment was estimated at USD 142 million in 2018 owing to rising awareness about early diagnosis.
Regional Analysis:
North America dominated the global bronchiectasis drugs market in 2017. The high prevalence of respiratory diseases, rising geriatric population, and technological advancements are some of the major factors responsible for its large share. Furthermore, increasing government funding for research & development activities is also expected to contribute towards its large share over the forecast period.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to a rise in disease prevalence and awareness drives by various organizations such as WHO & PDR-IACB among others.
The key players operating in this region include Actavis plc., Johnson & Johnson Services Inc., Pfizer Inc.
Growth Factors:
- Increasing incidence of bronchiectasis
- Growing awareness about the disease and its treatment options
- Rising demand for novel bronchiectasis drugs
- Technological advancements in drug delivery systems
- Growing number of clinical studies on new bronchiectasis drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Bronchiectasis Drugs Market Research Report
By Type
Antibiotics, Expectorants, Other drugs
By Application
Hospital, Research institute, Clinic, Other
By Companies
Endo International Plc, GlaxoSmithKline Plc, Neopharma LLC, Pfizer Inc., Reckitt Benckiser Group Plc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
150
Number of Tables & Figures
105
Customization Available
Yes, the report can be customized as per your need.
Global Bronchiectasis Drugs Market Report Segments:
The global Bronchiectasis Drugs market is segmented on the basis of:
Types
Antibiotics, Expectorants, Other drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Research institute, Clinic, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Endo International Plc
- GlaxoSmithKline Plc
- Neopharma LLC
- Pfizer Inc.
- Reckitt Benckiser Group Plc
Highlights of The Bronchiectasis Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antibiotics
- Expectorants
- Other drugs
- By Application:
- Hospital
- Research institute
- Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Bronchiectasis Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Bronchiectasis drugs are medications used to treat bronchitis and other breathing problems. These drugs can help improve airflow in the lungs, which may help reduce the symptoms of bronchiectasis.
Some of the major players in the bronchiectasis drugs market are Endo International Plc, GlaxoSmithKline Plc, Neopharma LLC, Pfizer Inc., Reckitt Benckiser Group Plc.
The bronchiectasis drugs market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Bronchiectasis Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Bronchiectasis Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Bronchiectasis Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Bronchiectasis Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Bronchiectasis Drugs Market Size & Forecast, 2018-2028
4.5.1 Bronchiectasis Drugs Market Size and Y-o-Y Growth
4.5.2 Bronchiectasis Drugs Market Absolute $ Opportunity
Chapter 5 Global Bronchiectasis Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Bronchiectasis Drugs Market Size Forecast by Type
5.2.1 Antibiotics
5.2.2 Expectorants
5.2.3 Other drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Bronchiectasis Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Bronchiectasis Drugs Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Research institute
6.2.3 Clinic
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Bronchiectasis Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Bronchiectasis Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Bronchiectasis Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Bronchiectasis Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Bronchiectasis Drugs Market Size Forecast by Type
9.6.1 Antibiotics
9.6.2 Expectorants
9.6.3 Other drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Bronchiectasis Drugs Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Research institute
9.10.3 Clinic
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Bronchiectasis Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Bronchiectasis Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Bronchiectasis Drugs Market Size Forecast by Type
10.6.1 Antibiotics
10.6.2 Expectorants
10.6.3 Other drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Bronchiectasis Drugs Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Research institute
10.10.3 Clinic
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Bronchiectasis Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Bronchiectasis Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Bronchiectasis Drugs Market Size Forecast by Type
11.6.1 Antibiotics
11.6.2 Expectorants
11.6.3 Other drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Bronchiectasis Drugs Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Research institute
11.10.3 Clinic
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Bronchiectasis Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Bronchiectasis Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Bronchiectasis Drugs Market Size Forecast by Type
12.6.1 Antibiotics
12.6.2 Expectorants
12.6.3 Other drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Bronchiectasis Drugs Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Research institute
12.10.3 Clinic
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Bronchiectasis Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Bronchiectasis Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Bronchiectasis Drugs Market Size Forecast by Type
13.6.1 Antibiotics
13.6.2 Expectorants
13.6.3 Other drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Bronchiectasis Drugs Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Research institute
13.10.3 Clinic
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Bronchiectasis Drugs Market: Competitive Dashboard
14.2 Global Bronchiectasis Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Endo International Plc
14.3.2 GlaxoSmithKline Plc
14.3.3 Neopharma LLC
14.3.4 Pfizer Inc.
14.3.5 Reckitt Benckiser Group Plc
